CEP-9722
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for CEP-9722, covering 2012-08-16 to 2024-01-30. Get the full timeline:
Most recent: Clinical Trial Update: Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors [Phase 1, Phase 2]